Main characteristics of 47 patients transplanted for HCV cirrhosis according to their initial immunosuppressive regimen
| Patient characteristics | Total (n=47) | CYA+AZA+PRED (n=31) | CYA+PRED (n=5) | CYA/TACR1-150 (n=11) |
|---|---|---|---|---|
| Sex (male/female) | 40/7 | 28/3 | 4/1 | 8/3 |
| Age (y), mean (SD) | 51 (10) | 51 (11) | 53 (7) | 50 (8) |
| HCC diagnosed pretransplant or at explant, n (%) | 11 (23.4) | 6 (19.4) | 0 | 5 (45.5) |
| Pretransplant alcohol abuse, n (%) | 7 (14.9) | 3 (9.7) | 1 (20.0) | 3 (27.3) |
| HCV genotype, n (%) | ||||
| 1a | 8 (17.0) | 5 (16.1) | 1 (20.0) | 2 (18.2) |
| 1b | 22 (46.9) | 15 (48.4) | 2 (40.0) | 5 (45.4) |
| 2 | 5 (10.6) | 2 (6.5) | 1 (20.0) | 2 (18.2) |
| 3 | 7 (14.9) | 6 (19.3) | 0 | 1 (9.1) |
| 4 | 5 (10.6) | 3 (9.7) | 1 (20.0) | 1 (9.1) |
| HLA mismatch, mean (SD) (in 29 patients) | 6.6 (1.2) | 6.5 (1.1) | 6.5 (1.0) | 6.6 (1.5) |
| Rejection episodes, mean (SD) | 1.7 (1.0) | 1.8 (1.1) | 1.0 (0.7) | 1.7 (1.0) |
| Methylprednisolone courses, mean (SD) | 1.2 (0.9) | 1.2 (0.8) | 1.6 (1.1) | 1.2 (1.2) |
| OKT3 for refractory rejection, n (%) | 3 (6) | 3 (10) | 0 | 0 |
| PRED duration (months), mean (SD) | 4.7 (3.5) | 6.5 (2.6) | 4.4 (1.1) | NA |
| Discontinuation of AZA, n (%) | 9 (19) | 9 (29) | NA | NA |
| Ganciclovir treatment, n (%) | 9 (19) | 5 (16) | 1 (20) | 3 (27) |
| CMV hepatitis, n (%) | 2 (4) | 1 (3) | 0 | 1 (9) |
| Acute hepatitis C, n (%) | 23 (49) | 12 (39) | 4 (80) | 7 (64) |
| Timing of acute hepatitis C†
(months after transplant), median (range) | 3 (0.5–11.0) | 3.0 (1.0–11.0) | 3.8 (1.5–7.0) | 1.5 (0.5–4.5) |
↵1-150 3/11 patients treated with TACR monotherapy; †only in the 23 patients with acute hepatitis C.
CYA, cyclosporin; AZA, azathioprine; PRED, prednisolone; TACR, tacrolimus; HCC, hepatocellular cancer; NA, not applicable.